Flow cytometric analysis of CD52 expression on Human PBMCs. Human PBMCs (human peripheral blood mononuclear cells) were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 Antibody and either PerCP-Cy5.5 Mouse IgG2a, κ Isotype Control (left panel) or PerCP-Cy5.5 Mouse Anti-Human CD52 Antibody (right panel) at 5 μl/test treated with True-Stain Monocyte Blocker™. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
PerCP-Cy5.5 Mouse Anti-Human CD52 Antibody (S-R445)
PerCP-Cy5.5 Mouse Anti-Human CD52 Antibody (S-R445)
Price:
Regular price
$120 USD
Regular price
Sale price
$120 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD52 |
| Synonyms | CAMPATH-1 antigen; CDw52; Cambridge pathology 1 antigen; Epididymal secretory protein E5; Human epididymis-specific protein 5 (He5); HE5 |
| Location | Cell membrane |
| Accession | P31358 |
| Clone Number | S-R445 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Isotype Control | S0B80056 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | PerCP-Cy5.5 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD52 is a small glycoprotein consisting of 12 amino acids, anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. It is widely expressed on the surface of various immune cells, including normal and malignant T and B lymphocytes, monocytes, and some epithelial cells. Although its exact biological function remains unclear, CD52 is believed to play roles in T-cell migration, activation, and immune regulation. Importantly, CD52 is the target of alemtuzumab, a humanized monoclonal antibody used to treat diseases like chronic lymphocytic leukemia (CLL) and multiple sclerosis. Alemtuzumab induces cell destruction through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Recent studies also suggest that CD52 may have immunosuppressive effects by binding to the SIGLEC-10 receptor and inhibiting T-cell function.
Picture
Picture
FC
